Upload extract stage outputs 2025-12-09T17:48:25.287210Z

manifest.json

@@ -1,5 +1,5 @@
 {
-  "generated_at": "2025-12-09T17:32:28.457753Z",
+  "generated_at": "2025-12-09T17:48:25.286956Z",
   "stage": "extract",
   "dataset": {
     "name": "HuggingFaceM4/FineVision",

sample_00000/document.md

@@ -26,20 +26,20 @@ Received: 21 April 2023 Accepted: 03 June 2023 Published: 07 June 2023
 
 ## References  
 
-1. Grando SA. Pemphigus autoimmunity: hypotheses and realities. Autoimmunity. 2012 Feb;45(1):7-35. doi: 10.3109/08916934.2011.606444.  
-2. Lever WF, Schaumburg-Lever G. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975. Arch Dermatol. 1977 Sep;113(9):1236-41. doi: 10.1001/archderm.1977.016400900084013.  
-3. Pasricha JS, Gupta R. Pulse therapy with dexamethasonecyclophosphamide in pemphigus. Indian J Dermatol Venereol Leprol. 1984; 50:199-203.  
+1. Grando SA. Pemphigus autoimmunity: hypotheses and realities. Autoimmunity. 2012 Feb;45(1):7-35. doi: 10.3109/08916934.2011.606444. 
+2. Lever WF, Schaumburg-Lever G. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975. Arch Dermatol. 1977 Sep;113(9):1236-41. doi: 10.1001/archderm.1977.016400900084013. 
+3. Pasricha JS, Gupta R. Pulse therapy with dexamethasonecyclophosphamide in pemphigus. Indian J Dermatol Venereol Leprol. 1984;50:199-203. 
 4. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol. 1996 Sep;132(2):203-12.  
 
-5. Heizmann M, Itin P, Wemli M, Borradori L, Bargetzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol. Feb 2001;66(2):142-4. doi: 10.1002/1096- 8652(200102)66:2<142::AID-AJH1032>3.0. CO;2-0.  
-6. Food and Drug Administration. Rituxan label; 2012 [cited Feb 2, 2021]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103705s5373lbl.pdf.  
-7. Belgi AS, Azeez M, Hoyle C, Williams REA. Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed. Clin Exp Dermatol. 2006 Jan;31(1):143. doi: 10.1111/j.1365- 2230.2005.01941. x.  
-8. Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebel M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2007 Feb;156(2):352-6. doi: 10.1111/j.1365- 2133.2006.07646. x.  
-9. Barrera MV, Mendiola MV, Bosch RJ, Herrera E. Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris. J Dermatol Treat. 2007 Jan;18(5):312-4. doi: 10.1080/09546630701323988.  
-10. Faurschou A, Gniadecki R. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int J Dermatol. 2008 Mar;47(3):292-4. doi: 10.1111/j.1365- 4632.2008.03423. x.  
-11. Craythorne EE, Mufti G, DuVivier AW. Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2011 Nov;65(5):1064-5. doi: 10.1016/j.jaad.2010.06.033.  
-12. Horváth B, Huizinga J, Pas HH, Mulder A, Jonkman MF. Low-dose rituximab is effective in pemphigus. Br J Dermatol. 2012 Feb;166(2):405-12. doi: 10.1111/j.1365- 2133.2011.10663. x.  
-13. Craythorne E, Du Vivier A, Mufti GJ, Warnakulasuriya S. Rituximab for the treatment of corticosteroid—refractory pemphigus vulgaris with oral and skin manifestations. J Oral Pathol Med. 2011 Sep;40(8):616-20. doi: 10.1111/j.1600- 0714.2011.01017. x  
-14. Kim JH, Kim YH, Kim MR, Kim SC. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol. 2011 Sep;165(3):646-51. doi: 10.1111/j.1365- 2133.2011.10411. x  
-15. Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011 Sep;65(3):552-8. doi: 10.1016/j.jaad.2010.07.032  
+5. Heizmann M, Itin P, Wermli M, Borradori L, Bargetzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol. Feb 2001;66(2):142-4. doi: 10.1002/1096-8652(200102)66:2<142::AID-AJH1032>3.0. CO;2-0. 
+6. Food and Drug Administration. Rituxan label; 2012 [cited Feb 2, 2021]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103705s5373lbl.pdf. 
+7. Belgi AS, Azeze M, Hoyle C, Williams REA. Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed. Clin Exp Dermatol. 2006 Jan;31(1):143. doi: 10.1111/j.1365-2230.2005.01941. x. 
+8. Schmidt E, Seitz CS, Benoit S, Brocker EB, Goebel M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2007 Feb;156(2):352-6. doi: 10.1111/j.1365-2133.2006.07646. x. 
+9. Barrera MV, Mendiola MV, Bosch RJ, Herrera E. Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris. J Dermatolog Treat. 2007 Jan;18(5):312-4. doi: 10.1080/09546630701323988. 
+10. Faurschou A, Gniadecki R. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int J Dermatol. 2008 Mar;47(3):292-4. doi: 10.1111/j.1365-4632.2008.03423. x. 
+11. Craythorne EE, Mufti G, DuVivier AW. Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2011 Nov;65(5):1064-5. doi: 10.1016/j.jaad.2010.06.033. 
+12. Horvath B, Huizinga J, Pas HH, Mulder AB, Jonkman MF. Low-dose rituximab is effective in pemphigus. Br J Dermatol. 2012 Feb;166(2):405-12. doi: 10.1111/j.1365-2133.2011.10663. x. 
+13. Craythorne E, Du Vivier A, Mufti GJ, Warnakulasuriya S. Rituximab for the treatment of corticosteroid—refractory pemphigus vulgaris with oral and skin manifestations. J Oral Pathol Med. 2011 Sep;40(8):616-20. doi: 10.1111/j.1600-0714.2011.01017. x 
+14. Kim JH, Kim YH, Kim MR, Kim SC. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol. 2011Sep;165(3):646-51. doi: 10.1111/j.1365-2133.2011.10411. x 
+15. Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011 Sep;65(3):552-8. doi: 10.1016/j.jaad.2010.07.032 
 16. Investor update. Basel; June 12, 2019. [cited Feb 5, 2021]. Available from: https://www.roche.com/investors/updates/inv-update-2019-06-12. htm.

sample_00000/raw_response.md

@@ -1,60 +1,60 @@
 21 April 2023 Accepted: 03 June 2023 Published: 07 June 2023  
 
-<|ref|>sub_title<|/ref|><|det|>[[93, 87, 368, 100]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[94, 88, 367, 100]]<|/det|>
 ## Ethics approval and consent to participate  
 
-<|ref|>text<|/ref|><|det|>[[92, 99, 485, 201]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[93, 101, 483, 201]]<|/det|>
 The study was conducted in accordance with the ethical principles of the Declaration of Helsinki (2013). Ethical approval was obtained from Sakhiya Skin Clinic, Surat, Gujarat, India. (Approval No: 2023/06). Consent forms were signed by patient. He was informed that he had the right to withdraw from the study at any time without any consequences. All pictures reported in this case- report study belong to Sakhiya Skin Clinic, Surat- 395003, Gujarat, India.  
 
-<|ref|>sub_title<|/ref|><|det|>[[92, 216, 246, 228]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[93, 217, 247, 229]]<|/det|>
 ## Consent for publication  
 
-<|ref|>text<|/ref|><|det|>[[92, 229, 179, 242]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[93, 230, 178, 242]]<|/det|>
 Not applicable  
 
-<|ref|>sub_title<|/ref|><|det|>[[92, 256, 219, 268]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[93, 257, 220, 269]]<|/det|>
 ## Competing interest  
 
-<|ref|>text<|/ref|><|det|>[[92, 268, 445, 281]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[93, 270, 445, 282]]<|/det|>
 The authors declare that they have no competing interests.  
 
-<|ref|>sub_title<|/ref|><|det|>[[92, 296, 177, 307]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[93, 297, 177, 308]]<|/det|>
 ## Open Access  
 
-<|ref|>text<|/ref|><|det|>[[92, 308, 485, 433]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[93, 309, 482, 433]]<|/det|>
 This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article unless otherwise stated.  
 
-<|ref|>sub_title<|/ref|><|det|>[[92, 448, 192, 460]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[93, 448, 192, 460]]<|/det|>
 ## Author Details  
 
-<|ref|>text<|/ref|><|det|>[[92, 461, 463, 515]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[92, 461, 461, 515]]<|/det|>
 1Department of Dermatology, Sakhiya Skin Clinic, Surat, Gujarat, India. 2Department of Medical Writing, Sakhiya Skin Clinic, Surat, Gujarat, India  
 
-<|ref|>sub_title<|/ref|><|det|>[[92, 529, 170, 540]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[93, 530, 170, 541]]<|/det|>
 ## Article Info  
 
-<|ref|>text<|/ref|><|det|>[[92, 542, 243, 580]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[92, 542, 244, 579]]<|/det|>
 Received: 21 April 2023 Accepted: 03 June 2023 Published: 07 June 2023  
 
-<|ref|>sub_title<|/ref|><|det|>[[92, 595, 167, 607]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[92, 595, 166, 606]]<|/det|>
 ## References  
 
-<|ref|>text<|/ref|><|det|>[[90, 607, 485, 784]]<|/det|>
-1. Grando SA. Pemphigus autoimmunity: hypotheses and realities. Autoimmunity. 2012 Feb;45(1):7-35. doi: 10.3109/08916934.2011.606444.  
-2. Lever WF, Schaumburg-Lever G. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975. Arch Dermatol. 1977 Sep;113(9):1236-41. doi: 10.1001/archderm.1977.016400900084013.  
-3. Pasricha JS, Gupta R. Pulse therapy with dexamethasonecyclophosphamide in pemphigus. Indian J Dermatol Venereol Leprol. 1984; 50:199-203.  
+<|ref|>text<|/ref|><|det|>[[92, 608, 483, 785]]<|/det|>
+1. Grando SA. Pemphigus autoimmunity: hypotheses and realities. Autoimmunity. 2012 Feb;45(1):7-35. doi: 10.3109/08916934.2011.606444. 
+2. Lever WF, Schaumburg-Lever G. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975. Arch Dermatol. 1977 Sep;113(9):1236-41. doi: 10.1001/archderm.1977.016400900084013. 
+3. Pasricha JS, Gupta R. Pulse therapy with dexamethasonecyclophosphamide in pemphigus. Indian J Dermatol Venereol Leprol. 1984;50:199-203. 
 4. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol. 1996 Sep;132(2):203-12.  
 
-<|ref|>text<|/ref|><|det|>[[514, 70, 906, 780]]<|/det|>
-5. Heizmann M, Itin P, Wemli M, Borradori L, Bargetzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol. Feb 2001;66(2):142-4. doi: 10.1002/1096- 8652(200102)66:2<142::AID-AJH1032>3.0. CO;2-0.  
-6. Food and Drug Administration. Rituxan label; 2012 [cited Feb 2, 2021]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103705s5373lbl.pdf.  
-7. Belgi AS, Azeez M, Hoyle C, Williams REA. Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed. Clin Exp Dermatol. 2006 Jan;31(1):143. doi: 10.1111/j.1365- 2230.2005.01941. x.  
-8. Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebel M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2007 Feb;156(2):352-6. doi: 10.1111/j.1365- 2133.2006.07646. x.  
-9. Barrera MV, Mendiola MV, Bosch RJ, Herrera E. Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris. J Dermatol Treat. 2007 Jan;18(5):312-4. doi: 10.1080/09546630701323988.  
-10. Faurschou A, Gniadecki R. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int J Dermatol. 2008 Mar;47(3):292-4. doi: 10.1111/j.1365- 4632.2008.03423. x.  
-11. Craythorne EE, Mufti G, DuVivier AW. Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2011 Nov;65(5):1064-5. doi: 10.1016/j.jaad.2010.06.033.  
-12. Horváth B, Huizinga J, Pas HH, Mulder A, Jonkman MF. Low-dose rituximab is effective in pemphigus. Br J Dermatol. 2012 Feb;166(2):405-12. doi: 10.1111/j.1365- 2133.2011.10663. x.  
-13. Craythorne E, Du Vivier A, Mufti GJ, Warnakulasuriya S. Rituximab for the treatment of corticosteroid—refractory pemphigus vulgaris with oral and skin manifestations. J Oral Pathol Med. 2011 Sep;40(8):616-20. doi: 10.1111/j.1600- 0714.2011.01017. x  
-14. Kim JH, Kim YH, Kim MR, Kim SC. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol. 2011 Sep;165(3):646-51. doi: 10.1111/j.1365- 2133.2011.10411. x  
-15. Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011 Sep;65(3):552-8. doi: 10.1016/j.jaad.2010.07.032  
+<|ref|>text<|/ref|><|det|>[[512, 73, 905, 782]]<|/det|>
+5. Heizmann M, Itin P, Wermli M, Borradori L, Bargetzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol. Feb 2001;66(2):142-4. doi: 10.1002/1096-8652(200102)66:2<142::AID-AJH1032>3.0. CO;2-0. 
+6. Food and Drug Administration. Rituxan label; 2012 [cited Feb 2, 2021]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103705s5373lbl.pdf. 
+7. Belgi AS, Azeze M, Hoyle C, Williams REA. Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed. Clin Exp Dermatol. 2006 Jan;31(1):143. doi: 10.1111/j.1365-2230.2005.01941. x. 
+8. Schmidt E, Seitz CS, Benoit S, Brocker EB, Goebel M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2007 Feb;156(2):352-6. doi: 10.1111/j.1365-2133.2006.07646. x. 
+9. Barrera MV, Mendiola MV, Bosch RJ, Herrera E. Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris. J Dermatolog Treat. 2007 Jan;18(5):312-4. doi: 10.1080/09546630701323988. 
+10. Faurschou A, Gniadecki R. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int J Dermatol. 2008 Mar;47(3):292-4. doi: 10.1111/j.1365-4632.2008.03423. x. 
+11. Craythorne EE, Mufti G, DuVivier AW. Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2011 Nov;65(5):1064-5. doi: 10.1016/j.jaad.2010.06.033. 
+12. Horvath B, Huizinga J, Pas HH, Mulder AB, Jonkman MF. Low-dose rituximab is effective in pemphigus. Br J Dermatol. 2012 Feb;166(2):405-12. doi: 10.1111/j.1365-2133.2011.10663. x. 
+13. Craythorne E, Du Vivier A, Mufti GJ, Warnakulasuriya S. Rituximab for the treatment of corticosteroid—refractory pemphigus vulgaris with oral and skin manifestations. J Oral Pathol Med. 2011 Sep;40(8):616-20. doi: 10.1111/j.1600-0714.2011.01017. x 
+14. Kim JH, Kim YH, Kim MR, Kim SC. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol. 2011Sep;165(3):646-51. doi: 10.1111/j.1365-2133.2011.10411. x 
+15. Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011 Sep;65(3):552-8. doi: 10.1016/j.jaad.2010.07.032 
 16. Investor update. Basel; June 12, 2019. [cited Feb 5, 2021]. Available from: https://www.roche.com/investors/updates/inv-update-2019-06-12. htm.

sample_00001/document.md

@@ -1,8 +1,6 @@
-Xylem's pump technologies and solutions have satisfied customers all over the world. The e-SH pump continues that tradition, with higher efficiencies and proven performance. Here are just a few of the markets and applications in which we're helping customers solve their water and fluid management challenges.  
+Yylem's pump technologies and solutions have satisfied customers all over the world. The e-SH pump continues that tradition, with higher efficiencies and proven performance. Here are just a few of the markets and applications in which we're helping customers solve their water and fluid management challenges.  
 
-- Water intake  
-
-- Water transfer and circulation- Pressure boosting- Process cooling and heating- Fluid transfer and transport- Produced water transfer and boosting- Boiler feed booster  
+- Water intake- Water transfer and circulation- Pressure boosting- Process cooling and heating- Fluid transfer and transport- Produced water transfer and boosting- Boiler feed booster  
 
 ## PUMPED FLUIDS  
 

sample_00001/raw_response.md

@@ -1,22 +1,19 @@
-Xylem's pump technologies and solutions have satisfied customers all over the world. The e-SH pump continues that tradition, with higher efficiencies and proven performance. Here are just a few of the markets and applications in which we're helping customers solve their water and fluid management challenges.  
+Yylem's pump technologies and solutions have satisfied customers all over the world. The e-SH pump continues that tradition, with higher efficiencies and proven performance. Here are just a few of the markets and applications in which we're helping customers solve their water and fluid management challenges.  
 
-<|ref|>text<|/ref|><|det|>[[56, 276, 182, 290]]<|/det|>
-- Water intake  
+<|ref|>text<|/ref|><|det|>[[56, 274, 354, 427]]<|/det|>
+- Water intake- Water transfer and circulation- Pressure boosting- Process cooling and heating- Fluid transfer and transport- Produced water transfer and boosting- Boiler feed booster  
 
-<|ref|>text<|/ref|><|det|>[[56, 299, 352, 426]]<|/det|>
-- Water transfer and circulation- Pressure boosting- Process cooling and heating- Fluid transfer and transport- Produced water transfer and boosting- Boiler feed booster  
-
-<|ref|>sub_title<|/ref|><|det|>[[56, 489, 288, 511]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[56, 490, 288, 512]]<|/det|>
 ## PUMPED FLUIDS  
 
-<|ref|>text<|/ref|><|det|>[[56, 520, 219, 655]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[55, 520, 216, 654]]<|/det|>
 - Groundwater- Potable water- Process water- Gray/used water- Heat transfer fluids- Produced water  
 
-<|ref|>sub_title<|/ref|><|det|>[[511, 275, 649, 290]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[512, 275, 649, 290]]<|/det|>
 ## SPECIFICATIONS  
 
-<|ref|>table<|/ref|><|det|>[[511, 298, 941, 619]]<|/det|>
+<|ref|>table<|/ref|><|det|>[[512, 297, 942, 619]]<|/det|>
 
 <table><tr><td>Maximum flow</td><td>1,140 gpm</td></tr><tr><td>Maximum head</td><td>464 ft. TDH</td></tr><tr><td>Maximum working pressure</td><td>230 psi</td></tr><tr><td>Maximum temperature</td><td>250 °F</td></tr><tr><td>Hydraulic performance</td><td>compliant with ANSI/HI 14.6 Grade 2B</td></tr><tr><td>Suction and discharge flanges</td><td>1&quot; - 4&quot; ANSI class 150 flanges</td></tr><tr><td>Motor</td><td>Standard 60 HZ NEMA premium efficient motors</td></tr></table>  
 
-<|ref|>image<|/ref|><|det|>[[0, 753, 997, 954]]<|/det|>
+<|ref|>image<|/ref|><|det|>[[0, 750, 999, 951]]<|/det|>

sample_00002/document.md

@@ -1,19 +1 @@
-3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3.  3. 3. 3. 3. 3. 3. 3. 3. 3. 3.  
-
-## Case presentation  
-
-A 39- year- old male patient who lives in Surat, Gujarat, was referred with a 3- month history of painful ulcerated lesions in the oral cavity. On enquiring about the patient's history, we came to know that initially, the patient had difficulty chewing food and the severity increased gradually. The ulcerations caused considerable discomfort, affecting his normal oral functions. Subsequently, fluid- filled lesions developed involving the scalp, trunk, limbs, and axilla. Lesions were increasing in size and number and had little tendency to heal. Blisters were flaccid and burst on their own to form erosions within 2- 3 days. Medical and family history was non- contributory. No history of fever, joint pain, malaise, and photosensitivity. He had weak oral hygiene due to the bad habit of taking betel quid with tobacco five times a day and smoking seven- - 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1 1. 1. 1. 1. 1. 1. 1. 1. 1. 1  
-
-![Figure sample_00002_fig01](figures/sample_00002_fig01.png)
-
-<center>Figure 1: Showing (a) ulcerative lesions present on the buccal mucosa (b) multiple vesicular lesions present on the face (c) multiple vesicular lesions with erosion present on the lower neck (d) multiple vesicular lesions present on the umbilicus (e) multiple vesicular lesions with erosion present on the upper limb (f) multiple vesicular lesions with erosion present on the back (g) multiple vesicular lesions with erosion on the axilla (h) flaccid blister lesions on the scalp (i) multiple vesicular lesions present on the dorsum of the penis. </center>  
-
-There was a positive Nikolsky sign and a bulla spread sign. The clinical manifestations of oral ulcers, flaccid bullae, and positive Nikolsky sign hinted at the provisional diagnosis of  
-
-PV. Mucous membrane pemphigoid, bullous lichen planus, paraneoplastic pemphigus, chronic ulcerative stomatitis, recurrent herpes lesions in immunocompromised patients, and erythema multiforme were the potential differential diagnosis of this condition. Regarding this, a biopsy was performed from a new vesicle to confirm the diagnosis. Histopathological examination revealed an intraepidermal supraslab acantholytic blister. Several acantholytic cells and neutrophils could be seen in the blister. The floor of the blister showed a tombstone pattern with occasional acantholytic cells. A moderately dense superficial perivascular mixed infiltrate was present in the dermis. Mild spongiosis with neutrophils was present at the periphery of the blister (Figure 2).  
-
-![Figure sample_00002_fig02](figures/sample_00002_fig02.png)
-
-<center>Figure 2: Photomicrograph showing acantholysis of the keratinocytes, tombstone appearance, epithelium exhibiting spongiosis, and superficial perivascular mixed infiltrate (H & E stain, x5). </center>  
-
-The hematological test had all findings within standard limits and, routine urine examination was unremarkable. In accordance with these findings, the definite diagnosis of PV was made and the treatment with oral cefuroxime (500mg twice a day) and oral prednisolone (20mg twice a day) with azathioprine (50mg twice a day) was started. Topical antibiotics and triamcinolone gel are advised for local application in the oral cavity. The dose of oral prednisolone was gradually tapered to 20mg, 10mg, 5mg, and 2.5mg (twice a day) every 30 days. The patient was maintained on the same dose of azathioprine (50mg twice a day) for one year. With the given therapy, complete remission was not achieved. Also, azathioprine was discontinued due to an elevated level of liver enzymes. Hence, the patient was shifted to rituximab therapy. The patient was initially given three doses of rituximab 1 gm each on days 1, 15, and 45. As premedication, ceftriaxone 1gm intravenously, hydrocortisone 100mg intravenously, paracetamol 650mg stat orally, and pheniramine maleate 2cc stat intravenously were given, sequentially on the day of infusion. After 30 minutes of these premedications rituximab (1gm) intravenously in 500ml of normal saline was given slowly over six to eight hours. The last dosage of rituximab was given after 3 months. A administration of rituximab lead to decrease Dsg 3 antibody levels which in turn resulted in the complete remission of the skin lesions within the next year (Figure 3a- g).
+0.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.3.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.4.1.1.1.1.1.1.1.1.1.1.1.1.1.1.5.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.6.1.1.1.1.1.1.1.1.1.1.1.1.1.1.7.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.8.1.1.1.1.1.1.1.1.1.1.1.1.1.1.9.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.10.1.1.1.1.1.1.1.1.1.1.1.1.1.1.11.1.1.1.1.1.1.1.1.1.1.1.1.1.1.12.1.1.1.1.1.1.1.1.1.1.1.1.1.13.1.1.1.1.1.1.1.1.1.1.1.1.1.1.14.1.1.1.1.1.1.1.1.1.1.1.1.1.15.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.16.1.1.1.1.1.1.1.1.1.1.1.1.1.17.1.1.1.1.1.1.1.1.1.1.1.1.1.1.18.1.1.1.1.1.1.1.1.1.1.1.1.1.1.19.1.1.1.1.1.1.1.1.1.1.1.1.1.1.20.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.21.1.1.1.1.1.1.1.1.1.1.1.1.1.1.22.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.23.1.1.1.1.1.1.1.1.1.1.1.1.1.1.24.1.1.1.1.1.1.1.1.1.1.1.1.1.25.1.1.1.1.1.1.1.1.1.1.1.1.1.1.26.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.27.1.1.1.1.1.1.1.1.1.1.1.1.1.1.28.1.1.1.1.1.1.1.1.1.1.1.1.1.1.29.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.30.1.1.1.1.1.1.1.1.1.1.1.1.1.1.31.1.1.1.1.1.1.1.1.1.1.1.1.1.1.32.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.33.1.1.1.1.1.1.1.1.1.1.1.1.1.1.34.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.35.1.1.1.1.1.1.1.1.1.1.1.1.1.1.36.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.37.1.1.1.1.1.1.1.1.1.1.1.1.1.1.38.1.1.1.1.1.1.1.1.1.1.1.1.1.1.39.1.1.1.1.1.1.1.1.1.1.1.1.1.1.40.1.1.1.1.1.1.1.1.1.1.1.1.1.1.41.1.1.1.1.1.1.1.1.1.1.1.1.1.1.42.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.43.1.1.1.1.1.1.1.1.1.1.1.1.1.1.44.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.45.1.1.1.1.1.1.1.1.1.1.1.1.1.1.46.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.47.1.1.1.1.1.1.1.1.1.1.1.1.1.1.48.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.49.1.1.1.1.1.1.1.1.1.1.1.1.1.1.50.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.51.1.1.1.1.1.1.1.1.1.1.1.1.1.1.52.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.53.1.1.1.1.1.1.1.1.1.1.1.1.1.1.54.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.55.1.1.1.1.1.1.1.1.1.1.1.1.1.1.56.1.1.1.1.1.1.1.1.1.1.1.1.1.1.57.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.58.1.1.1.1.1.1.1.1.1.1.1.1.1.1.59.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.60.1.1.1.1.1.1.1.1.1.1.1.1.1.1.61.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.62.1.1.1.1.1.1.1.1.1.1.1.1.1.1.63.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.64.1.1.1.1.1.1.1.1.1.1.1.1.1.1.65.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.66.1.1.1.1.1.1.1.1.1.1.1.1.1.1.67.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.68.1.1.1.1.1.1.1.1.1.1.1.1.1.1.69.1.1.1.1.1.1.1.1.1.1.1.1.1.1.70.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.71.1.1.1.1.1.1.1.1.1.1.1.1.1.1.72.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.73.1.1.1.1.1.1.1.1.1.1.1.1.1.1.74.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.75.1.1.1.1.1.1.1.1.1.1.1.1.1.1.76.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.77.1.1.1.1.1.1.1.1.1.1.1.1.1.1.78.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.79.1.1.1.1.1.1.1.1.1.1.1.1.1.1.80.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.81.1.1.1.1.1.1.1.1.1.1.1.1.1.1.82.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.83.1.1.1.1.1.1.1.1.1.1.1.1.1.1.84.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.85.1.1.1.1.1.1.1.1.1.1.1.1.1.1.86.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.87.1.1.1.1.1.1.1.1.1.1.1.1.1.1.88.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.89.1.1.1.1.1.1.1.1.1.1.1.1.1.1.90.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.91.1.1.1.1.1.1.1.1.1.1.1.1.1.1.92.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.93.1.1.1.1.1.1.1.1.1.1.1.1.1.1.94.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.95.1.1.1.1.1.1.1.1.1.1.1.1.1.1.96.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.97.1.1.1.1.1.1.1.1.1.1.1.1.1.1.98.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.99.1.1.1.1.1.1.1.1.1.1.1.1.1.1.100.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.101.1.1.1.1.1.1.1.1.1.1.1.1.1.1.102.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.103.1.1.1.1.1.1.1.1.1.1.1.1.1.1.104.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.105.1.1.1.1.1.1.1.1.1.1.1.1.1.1.106.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.107.1.1.1.1.1.1.1.1.1.1.1.1.1.1.108.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.109.1.1.1.1.1.1.1.1.1.1.1.1.1.1.110.1.1.1.1.1.1.1.1.1.1.1.1.1.1.111.1.1.1.1.1.1.1.1.1.1.1.1.1.1.112.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.113.1.1.1.1.1.1.1.1.1.1.1.1.1.1.114.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.115.1.1.1.1.1.1.1.1.1.1.1.1.1.1.116.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.117.1.1.1.1.1.1.1.1.1.1.1.1.1.1.118.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.119.1.1.1.1.1.1.1.1.1.1.1.1.1.1.120.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.121.1.1.1.1.1.1.1.1.1.1.1.1.1.1.122.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.123.1.1.1.1.1.1.1.1.1.1.1.1.1.1.124.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.125.1.1.1.1.1.1.1.1.1.1.1.1.1.1.126.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.127.1.1.1.1.1.1.1.1.1.1.1.1.1.1.128.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.129.1.1.1.1.1.1.1.1.1.1.1.1.1.1.130.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.131.1.1.1.1.1.1.1.1.1.1.1.1.1.1.132.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.133.1.1.1.1.1.1.1.1.1.1.1.1.1.1.

sample_00002/raw_response.md

@@ -1,24 +1 @@
-3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3.  3. 3. 3. 3. 3. 3. 3. 3. 3. 3.  
-
-<|ref|>sub_title<|/ref|><|det|>[[93, 156, 235, 171]]<|/det|>
-## Case presentation  
-
-<|ref|>text<|/ref|><|det|>[[93, 172, 483, 499]]<|/det|>
-A 39- year- old male patient who lives in Surat, Gujarat, was referred with a 3- month history of painful ulcerated lesions in the oral cavity. On enquiring about the patient's history, we came to know that initially, the patient had difficulty chewing food and the severity increased gradually. The ulcerations caused considerable discomfort, affecting his normal oral functions. Subsequently, fluid- filled lesions developed involving the scalp, trunk, limbs, and axilla. Lesions were increasing in size and number and had little tendency to heal. Blisters were flaccid and burst on their own to form erosions within 2- 3 days. Medical and family history was non- contributory. No history of fever, joint pain, malaise, and photosensitivity. He had weak oral hygiene due to the bad habit of taking betel quid with tobacco five times a day and smoking seven- - 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1 1. 1. 1. 1. 1. 1. 1. 1. 1. 1  
-
-<|ref|>image<|/ref|><|det|>[[93, 512, 482, 797]]<|/det|>
-<|ref|>image_caption<|/ref|><|det|>[[92, 799, 483, 866]]<|/det|>
-<center>Figure 1: Showing (a) ulcerative lesions present on the buccal mucosa (b) multiple vesicular lesions present on the face (c) multiple vesicular lesions with erosion present on the lower neck (d) multiple vesicular lesions present on the umbilicus (e) multiple vesicular lesions with erosion present on the upper limb (f) multiple vesicular lesions with erosion present on the back (g) multiple vesicular lesions with erosion on the axilla (h) flaccid blister lesions on the scalp (i) multiple vesicular lesions present on the dorsum of the penis. </center>  
-
-<|ref|>text<|/ref|><|det|>[[92, 879, 483, 920]]<|/det|>
-There was a positive Nikolsky sign and a bulla spread sign. The clinical manifestations of oral ulcers, flaccid bullae, and positive Nikolsky sign hinted at the provisional diagnosis of  
-
-<|ref|>text<|/ref|><|det|>[[514, 71, 904, 256]]<|/det|>
-PV. Mucous membrane pemphigoid, bullous lichen planus, paraneoplastic pemphigus, chronic ulcerative stomatitis, recurrent herpes lesions in immunocompromised patients, and erythema multiforme were the potential differential diagnosis of this condition. Regarding this, a biopsy was performed from a new vesicle to confirm the diagnosis. Histopathological examination revealed an intraepidermal supraslab acantholytic blister. Several acantholytic cells and neutrophils could be seen in the blister. The floor of the blister showed a tombstone pattern with occasional acantholytic cells. A moderately dense superficial perivascular mixed infiltrate was present in the dermis. Mild spongiosis with neutrophils was present at the periphery of the blister (Figure 2).  
-
-<|ref|>image<|/ref|><|det|>[[514, 269, 905, 507]]<|/det|>
-<|ref|>image_caption<|/ref|><|det|>[[513, 511, 904, 552]]<|/det|>
-<center>Figure 2: Photomicrograph showing acantholysis of the keratinocytes, tombstone appearance, epithelium exhibiting spongiosis, and superficial perivascular mixed infiltrate (H & E stain, x5). </center>  
-
-<|ref|>text<|/ref|><|det|>[[513, 568, 904, 924]]<|/det|>
-The hematological test had all findings within standard limits and, routine urine examination was unremarkable. In accordance with these findings, the definite diagnosis of PV was made and the treatment with oral cefuroxime (500mg twice a day) and oral prednisolone (20mg twice a day) with azathioprine (50mg twice a day) was started. Topical antibiotics and triamcinolone gel are advised for local application in the oral cavity. The dose of oral prednisolone was gradually tapered to 20mg, 10mg, 5mg, and 2.5mg (twice a day) every 30 days. The patient was maintained on the same dose of azathioprine (50mg twice a day) for one year. With the given therapy, complete remission was not achieved. Also, azathioprine was discontinued due to an elevated level of liver enzymes. Hence, the patient was shifted to rituximab therapy. The patient was initially given three doses of rituximab 1 gm each on days 1, 15, and 45. As premedication, ceftriaxone 1gm intravenously, hydrocortisone 100mg intravenously, paracetamol 650mg stat orally, and pheniramine maleate 2cc stat intravenously were given, sequentially on the day of infusion. After 30 minutes of these premedications rituximab (1gm) intravenously in 500ml of normal saline was given slowly over six to eight hours. The last dosage of rituximab was given after 3 months. A administration of rituximab lead to decrease Dsg 3 antibody levels which in turn resulted in the complete remission of the skin lesions within the next year (Figure 3a- g).
+0.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.3.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.4.1.1.1.1.1.1.1.1.1.1.1.1.1.1.5.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.6.1.1.1.1.1.1.1.1.1.1.1.1.1.1.7.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.8.1.1.1.1.1.1.1.1.1.1.1.1.1.1.9.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.10.1.1.1.1.1.1.1.1.1.1.1.1.1.1.11.1.1.1.1.1.1.1.1.1.1.1.1.1.1.12.1.1.1.1.1.1.1.1.1.1.1.1.1.13.1.1.1.1.1.1.1.1.1.1.1.1.1.1.14.1.1.1.1.1.1.1.1.1.1.1.1.1.15.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.16.1.1.1.1.1.1.1.1.1.1.1.1.1.17.1.1.1.1.1.1.1.1.1.1.1.1.1.1.18.1.1.1.1.1.1.1.1.1.1.1.1.1.1.19.1.1.1.1.1.1.1.1.1.1.1.1.1.1.20.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.21.1.1.1.1.1.1.1.1.1.1.1.1.1.1.22.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.23.1.1.1.1.1.1.1.1.1.1.1.1.1.1.24.1.1.1.1.1.1.1.1.1.1.1.1.1.25.1.1.1.1.1.1.1.1.1.1.1.1.1.1.26.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.27.1.1.1.1.1.1.1.1.1.1.1.1.1.1.28.1.1.1.1.1.1.1.1.1.1.1.1.1.1.29.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.30.1.1.1.1.1.1.1.1.1.1.1.1.1.1.31.1.1.1.1.1.1.1.1.1.1.1.1.1.1.32.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.33.1.1.1.1.1.1.1.1.1.1.1.1.1.1.34.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.35.1.1.1.1.1.1.1.1.1.1.1.1.1.1.36.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.37.1.1.1.1.1.1.1.1.1.1.1.1.1.1.38.1.1.1.1.1.1.1.1.1.1.1.1.1.1.39.1.1.1.1.1.1.1.1.1.1.1.1.1.1.40.1.1.1.1.1.1.1.1.1.1.1.1.1.1.41.1.1.1.1.1.1.1.1.1.1.1.1.1.1.42.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.43.1.1.1.1.1.1.1.1.1.1.1.1.1.1.44.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.45.1.1.1.1.1.1.1.1.1.1.1.1.1.1.46.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.47.1.1.1.1.1.1.1.1.1.1.1.1.1.1.48.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.49.1.1.1.1.1.1.1.1.1.1.1.1.1.1.50.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.51.1.1.1.1.1.1.1.1.1.1.1.1.1.1.52.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.53.1.1.1.1.1.1.1.1.1.1.1.1.1.1.54.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.55.1.1.1.1.1.1.1.1.1.1.1.1.1.1.56.1.1.1.1.1.1.1.1.1.1.1.1.1.1.57.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.58.1.1.1.1.1.1.1.1.1.1.1.1.1.1.59.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.60.1.1.1.1.1.1.1.1.1.1.1.1.1.1.61.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.62.1.1.1.1.1.1.1.1.1.1.1.1.1.1.63.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.64.1.1.1.1.1.1.1.1.1.1.1.1.1.1.65.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.66.1.1.1.1.1.1.1.1.1.1.1.1.1.1.67.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.68.1.1.1.1.1.1.1.1.1.1.1.1.1.1.69.1.1.1.1.1.1.1.1.1.1.1.1.1.1.70.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.71.1.1.1.1.1.1.1.1.1.1.1.1.1.1.72.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.73.1.1.1.1.1.1.1.1.1.1.1.1.1.1.74.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.75.1.1.1.1.1.1.1.1.1.1.1.1.1.1.76.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.77.1.1.1.1.1.1.1.1.1.1.1.1.1.1.78.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.79.1.1.1.1.1.1.1.1.1.1.1.1.1.1.80.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.81.1.1.1.1.1.1.1.1.1.1.1.1.1.1.82.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.83.1.1.1.1.1.1.1.1.1.1.1.1.1.1.84.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.85.1.1.1.1.1.1.1.1.1.1.1.1.1.1.86.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.87.1.1.1.1.1.1.1.1.1.1.1.1.1.1.88.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.89.1.1.1.1.1.1.1.1.1.1.1.1.1.1.90.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.91.1.1.1.1.1.1.1.1.1.1.1.1.1.1.92.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.93.1.1.1.1.1.1.1.1.1.1.1.1.1.1.94.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.95.1.1.1.1.1.1.1.1.1.1.1.1.1.1.96.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.97.1.1.1.1.1.1.1.1.1.1.1.1.1.1.98.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.99.1.1.1.1.1.1.1.1.1.1.1.1.1.1.100.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.101.1.1.1.1.1.1.1.1.1.1.1.1.1.1.102.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.103.1.1.1.1.1.1.1.1.1.1.1.1.1.1.104.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.105.1.1.1.1.1.1.1.1.1.1.1.1.1.1.106.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.107.1.1.1.1.1.1.1.1.1.1.1.1.1.1.108.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.109.1.1.1.1.1.1.1.1.1.1.1.1.1.1.110.1.1.1.1.1.1.1.1.1.1.1.1.1.1.111.1.1.1.1.1.1.1.1.1.1.1.1.1.1.112.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.113.1.1.1.1.1.1.1.1.1.1.1.1.1.1.114.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.115.1.1.1.1.1.1.1.1.1.1.1.1.1.1.116.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.117.1.1.1.1.1.1.1.1.1.1.1.1.1.1.118.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.119.1.1.1.1.1.1.1.1.1.1.1.1.1.1.120.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.121.1.1.1.1.1.1.1.1.1.1.1.1.1.1.122.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.123.1.1.1.1.1.1.1.1.1.1.1.1.1.1.124.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.125.1.1.1.1.1.1.1.1.1.1.1.1.1.1.126.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.127.1.1.1.1.1.1.1.1.1.1.1.1.1.1.128.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.129.1.1.1.1.1.1.1.1.1.1.1.1.1.1.130.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.131.1.1.1.1.1.1.1.1.1.1.1.1.1.1.132.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.133.1.1.1.1.1.1.1.1.1.1.1.1.1.1.

sample_00003/raw_response.md

@@ -12,7 +12,7 @@
 <|ref|>sub_title<|/ref|><|det|>[[511, 307, 751, 385]]<|/det|>
 ## AQUAVAR® IPC VARIABLE SPEED CONTROLLER  
 
-<|ref|>sub_title<|/ref|><|det|>[[512, 431, 597, 446]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[512, 430, 597, 444]]<|/det|>
 ## FEATURES  
 
 <|ref|>text<|/ref|><|det|>[[511, 451, 934, 955]]<|/det|>

sample_00004/document.md

@@ -1,8 +1,10 @@
-2645-9248 Journal homepage: www.jidhealth.com 0pen A ccess  
+2645-9248 Journal homepage: www.jidhealth.com Open A ccess  
 
-# A case report on generalized pemphigus vulgaris treated with rituximaba  
+Original Article  
 
-J agdish J adavbhai Sakhiya \(^{1\ast}\) , Dhruv J agdish Sakhiya \(^{1}\) , J ashmine Mukeshbhai Gandhi \(^{1}\) , Feral Ravi Daruwala \(^{2}\)  
+# A case report on generalized pemphigus vulgaris treated with rituximab  
+
+J agdish J adavbhai Sakhiya \(^{1*}\) , Dhruv J agdish Sakhiya \(^{1}\) , J ashmine Mukeshbhai Gandhi \(^{1}\) , Feral Ravi Daruwala \(^{2}\)  
 
 ## Abstract  
 
@@ -16,6 +18,6 @@ Keywords: Autoantibodies; Pemphigus, Rituximab, Oral Hygiene, Ulceration, Tobacc
 
 ## Background  
 
-The term pemphigus implies a group of autoimmune, mucocutaneous blistering diseases, in which the keratinocyte antigens are the target of the autoantibodies, prompting acantholysis and the formation of blisters. Main variants of pemphigus include pemphigus vulgaris (PV) and pemphigus foliaceus (PF). PV is the most common subtype and represents well over \(80\%\) of cases. As being a serious and potentially lifethreatening condition, early treatment is of utmost importance [1]. The advent of corticosteroids in the amelioration of pemphigus has dramatically changed the outlook of this perpetually disastrous disease; thus, corticosteroids have become the cornerstone of pemphigus therapy. One case reported favorable outcomes with combined therapy of high- dose corticosteroids and other immunosuppressants. However, such a high dose of corticosteroids can cause serious adverse events such as several metabolic problems, global reduction of  
+The term pemphigus implies a group of autoimmune, mucocutaneous blistering diseases, in which the keratinocyte antigens are the target of the autoantibodies, prompting acantholysis and the formation of blisters. Main variants of pemphigus include pemphigus vulgaris (PV) and pemphigus foliaceus (PF). PV is the most common subtype and represents well over \(80\%\) of cases. As being a serious and potentially lifethreatening condition, early treatment is of utmost importance [1]. The advent of corticosteroids in the amelioration of pemphigus has dramatically changed the outlook of this perpetually disastrous disease; thus, corticosteroids have become the cornerstone of pemphigus therapy. One case reported favorable outcomes with combined therapy of highdose corticosteroids and other immunosuppressants. However, such a high dose of corticosteroids can cause serious adverse events such as several metabolic problems, global reduction of  
 
 immune system efficacy, antecedent risk of serious infections, and mortality [2]. To overcome these long- term events, Pasricha and Gupta introduced dexamethasone cyclophosphamide pulse (DCP) therapy in 1984 [3]. Later on, DCP and oral corticosteroids with or without adjuvant immunosuppressants (azathioprine, cyclophosphamide, mycophenolate mofetil, and cyclosporine) have emerged as the backbone of pemphigus treatment, however, they are associated with the high death rate in pemphigus [4]. With these conventional treatments, some patients fail to improve or some have contraindications for their usage, or some encounter relapse. Hence, advanced research has continuously been going on for finding newer molecules in pemphigus. In 2001, Heizmann et al. [5] first used rituximab for the therapy of autoimmune bullous diseases. He reported a case of paraneoplastic pemphigus favorably managed with rituximab, since then there was a drastic development in the pemphigus treatment era. Rituximab chimeric monoclonal antibody selectively acts on the CD20 expressing B cells, which are known to secrete auto- antibodies targeting the epidermal desmogleins (DSG). It has been used nearly in one million patients for treating lymphoma worldwide. Recently, rituximab has been approved for rheumatoid arthritis that is unresponsive

sample_00004/raw_response.md

@@ -1,31 +1,34 @@
-2645-9248 Journal homepage: www.jidhealth.com 0pen A ccess  
+2645-9248 Journal homepage: www.jidhealth.com Open A ccess  
 
-<|ref|>title<|/ref|><|det|>[[87, 216, 794, 265]]<|/det|>
-# A case report on generalized pemphigus vulgaris treated with rituximaba  
+<|ref|>text<|/ref|><|det|>[[87, 180, 203, 192]]<|/det|>
+Original Article  
 
-<|ref|>text<|/ref|><|det|>[[87, 291, 894, 327]]<|/det|>
-J agdish J adavbhai Sakhiya \(^{1\ast}\) , Dhruv J agdish Sakhiya \(^{1}\) , J ashmine Mukeshbhai Gandhi \(^{1}\) , Feral Ravi Daruwala \(^{2}\)  
+<|ref|>title<|/ref|><|det|>[[87, 215, 795, 265]]<|/det|>
+# A case report on generalized pemphigus vulgaris treated with rituximab  
 
-<|ref|>sub_title<|/ref|><|det|>[[102, 350, 175, 363]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[87, 292, 895, 326]]<|/det|>
+J agdish J adavbhai Sakhiya \(^{1*}\) , Dhruv J agdish Sakhiya \(^{1}\) , J ashmine Mukeshbhai Gandhi \(^{1}\) , Feral Ravi Daruwala \(^{2}\)  
+
+<|ref|>sub_title<|/ref|><|det|>[[101, 351, 175, 364]]<|/det|>
 ## Abstract  
 
-<|ref|>text<|/ref|><|det|>[[101, 366, 876, 404]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[101, 367, 876, 404]]<|/det|>
 Background: Pemphigus vulgaris has an obscure etiology; the presence of autoantibodies is coherent with an autoimmune disease. Rituximab a monoclonal antibody that specifically targets the CD20 antigen of B lymphocytes, has arisen as a novel treatment approach for pemphigus vulgaris.  
 
-<|ref|>text<|/ref|><|det|>[[101, 413, 888, 476]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[101, 412, 887, 476]]<|/det|>
 Case presentation: A 39- year- old male patient presented with a three- month history of mouth ulcers, poor oral hygiene accompanied with heavy tobacco smoking and alcohol consumption. He was diagnosed with pemphigus vulgaris. The disease gradually progressed to involve other body parts. The patient had shown partial improvement after conventional therapy (oral cefuroxime, oral prednisolone with azathioprine) and was later on successfully treated with rituximab. After 90 days of follow- up, no future recurrence was observed.  
 
-<|ref|>text<|/ref|><|det|>[[100, 486, 893, 514]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[101, 486, 889, 514]]<|/det|>
 Conclusion: With this case, the authors would like to aware other clinicians of the potential use of rituximab in treating pemphigus vulgaris, especially when the conventional therapy fails.  
 
-<|ref|>text<|/ref|><|det|>[[100, 523, 815, 557]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[101, 524, 813, 558]]<|/det|>
 Keywords: Autoantibodies; Pemphigus, Rituximab, Oral Hygiene, Ulceration, Tobacco Smoking, Alcohol consumption, India  
 
-<|ref|>sub_title<|/ref|><|det|>[[92, 594, 192, 609]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[91, 594, 192, 608]]<|/det|>
 ## Background  
 
-<|ref|>text<|/ref|><|det|>[[92, 610, 484, 835]]<|/det|>
-The term pemphigus implies a group of autoimmune, mucocutaneous blistering diseases, in which the keratinocyte antigens are the target of the autoantibodies, prompting acantholysis and the formation of blisters. Main variants of pemphigus include pemphigus vulgaris (PV) and pemphigus foliaceus (PF). PV is the most common subtype and represents well over \(80\%\) of cases. As being a serious and potentially lifethreatening condition, early treatment is of utmost importance [1]. The advent of corticosteroids in the amelioration of pemphigus has dramatically changed the outlook of this perpetually disastrous disease; thus, corticosteroids have become the cornerstone of pemphigus therapy. One case reported favorable outcomes with combined therapy of high- dose corticosteroids and other immunosuppressants. However, such a high dose of corticosteroids can cause serious adverse events such as several metabolic problems, global reduction of  
+<|ref|>text<|/ref|><|det|>[[91, 609, 483, 835]]<|/det|>
+The term pemphigus implies a group of autoimmune, mucocutaneous blistering diseases, in which the keratinocyte antigens are the target of the autoantibodies, prompting acantholysis and the formation of blisters. Main variants of pemphigus include pemphigus vulgaris (PV) and pemphigus foliaceus (PF). PV is the most common subtype and represents well over \(80\%\) of cases. As being a serious and potentially lifethreatening condition, early treatment is of utmost importance [1]. The advent of corticosteroids in the amelioration of pemphigus has dramatically changed the outlook of this perpetually disastrous disease; thus, corticosteroids have become the cornerstone of pemphigus therapy. One case reported favorable outcomes with combined therapy of highdose corticosteroids and other immunosuppressants. However, such a high dose of corticosteroids can cause serious adverse events such as several metabolic problems, global reduction of  
 
-<|ref|>text<|/ref|><|det|>[[512, 594, 904, 902]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[513, 592, 903, 902]]<|/det|>
 immune system efficacy, antecedent risk of serious infections, and mortality [2]. To overcome these long- term events, Pasricha and Gupta introduced dexamethasone cyclophosphamide pulse (DCP) therapy in 1984 [3]. Later on, DCP and oral corticosteroids with or without adjuvant immunosuppressants (azathioprine, cyclophosphamide, mycophenolate mofetil, and cyclosporine) have emerged as the backbone of pemphigus treatment, however, they are associated with the high death rate in pemphigus [4]. With these conventional treatments, some patients fail to improve or some have contraindications for their usage, or some encounter relapse. Hence, advanced research has continuously been going on for finding newer molecules in pemphigus. In 2001, Heizmann et al. [5] first used rituximab for the therapy of autoimmune bullous diseases. He reported a case of paraneoplastic pemphigus favorably managed with rituximab, since then there was a drastic development in the pemphigus treatment era. Rituximab chimeric monoclonal antibody selectively acts on the CD20 expressing B cells, which are known to secrete auto- antibodies targeting the epidermal desmogleins (DSG). It has been used nearly in one million patients for treating lymphoma worldwide. Recently, rituximab has been approved for rheumatoid arthritis that is unresponsive

sample_00005/raw_response.md

@@ -30,10 +30,10 @@
 <|ref|>text<|/ref|><|det|>[[510, 286, 886, 359]]<|/det|>
 The dose recommendations for FDG, MET, and FET mentioned here are valid for full ring dedicated PET- cameras with BGO- crystals in 3D- mode.  
 
-<|ref|>text<|/ref|><|det|>[[510, 361, 886, 511]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[510, 361, 886, 509]]<|/det|>
 - FDG: in adults, 125-250 MBq (typically 150 MBq) in 3D-mode. In children, 2-4 MBq/kg in 3D-mode with a minimum of 10 MBq in newborn infants.- IMT: 100-400 MBq (typically 185 MBq).- MET: 200-250 MBq.- FET: 200-250 MBq.  
 
-<|ref|>text<|/ref|><|det|>[[510, 522, 886, 692]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[510, 521, 886, 692]]<|/det|>
 The administered dose may increase using 2D- mode and vary for other systems according to differences in sensitivity. For the radiolabeled amino acids, the activity to be administered to children should be a fraction of the adult activity calculated from body weight according to the factors given by the EANM Pediatric Task Group.  
 
 <|ref|>sub_title<|/ref|><|det|>[[511, 722, 775, 739]]<|/det|>
@@ -42,5 +42,5 @@ The administered dose may increase using 2D- mode and vary for other systems acc
 <|ref|>sub_title<|/ref|><|det|>[[510, 749, 865, 784]]<|/det|>
 ## Radiation Dosimetry of Brain Transmission Scans  
 
-<|ref|>text<|/ref|><|det|>[[510, 793, 885, 903]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[510, 793, 886, 902]]<|/det|>
 Based on transmission scans of 10 min and CT- based scans of 5- 10 s, the effective doses per scan are: 20- 30 \(\mu \mathrm{Sv}\) for Germanium- based transmission, \(\sim 20 \mu \mathrm{Sv}\) for low- dose high- speed CT, and between 220 and \(450 \mu \mathrm{Sv}\) for high- quality CT.

sample_00006/document.md

@@ -1,69 +1,59 @@
-1? (X) 
+1? (X)  
 
-Entry for the Engineers Ireland
-Biomedical Research Medal? (X) 
+Entry for the Engineers Ireland Biomedical Research Medal? (X)  
 
-Mature Researcher (Beyond PhD Year 1?) 
+![Figure sample_00006_fig01](figures/sample_00006_fig01.png)  
 
-Post-Doctoral Researcher/Senior Researcher/PI 
+![Figure sample_00006_fig02](figures/sample_00006_fig02.png)  
 
-Y 
+![Figure sample_00006_fig03](figures/sample_00006_fig03.png)  
 
-Y 
+Mature Researcher (Beyond PhD Year 1?)  
 
-N 
+Post- Doctoral Researcher/Senior Researcher/PI  
 
-N 
+![Figure sample_00006_fig04](figures/sample_00006_fig04.png)  
 
-LOAD INDUCED CHANGES IN COLLAGEN FIBRE ARCHITECTURE IN ARTERIES
-CHARACTERISED BY SMALL ANGLE LIGHT SCATTERING 
+# LOAD INDUCED CHANGES IN COLLAGEN FIBRE ARCHITECTURE IN ARTERIES CHARACTERISED BY SMALL ANGLE LIGHT SCATTERING  
 
-Gaul, R.¹,², Lally, C.¹,² 
+Gaul, R.1,2, Lally, C.1,2 1Trinity Centre for Bioengineering, Trinity College Dublin, Dublin, Ireland. 2School of Engineering, Trinity College Dublin, Dublin, Ireland. email: rgau@tcd.ie  
 
-¹Trinity Centre for Bioengineering, Trinity College Dublin, Dublin, Ireland. 
+## INTRODUCTION  
 
-²School of Engineering, Trinity College Dublin, Dublin, Ireland. 
+The structural strength of arteries is governed by reinforcing collagen fibres present in the vessel wall. Although healthy vessels are capable of fibre remodelling, unhealthy fibre remodelling patterns may be associated with disease [1]. A greater understanding of the remodelling of these fibres may provide greater insight into arteries at risk of disease and how arterial repair may be induced.  
 
-email: rgau@tcd.ie 
+Small angle light scattering (SALS) is a technique which has previously been used to determine the structure of thin, highly organised tissue structures, such as bovine pericardium and porcine aortic valve tissue [2].  
 
-INTRODUCTION 
+The aim of the present study is to design and develop a fully automated SALS system capable of determining the changes in arterial fibre architecture in response to strain.  
 
-The structural strength of arteries is governed by reinforcing collagen fibres present in the vessel wall. Although healthy vessels are capable of fibre remodelling, unhealthy fibre remodelling patterns may be associated with disease [1]. A greater understanding of the remodelling of these fibres may provide greater insight into arteries at risk of disease and how arterial repair may be induced. 
+## MATERIALS AND METHODS  
 
-Small angle light scattering (SALS) is a technique which has previously been used to determine the structure of thin, highly organised tissue structures, such as bovine pericardium and porcine aortic valve tissue [2]. 
+An in- house SALS system has been developed making use of an unpolarised 5mW HeNe laser \((\lambda = 632.8 \text{nm})\) and two focusing lenses in order to pass light through a tissue sample held in an automated sample positioner. The sample positioner incorporates two stepper motors controlled by LabVIEW to allow movement of the sample in the x and y plane with a resolution of \(5 \mu \text{m}\) . The sample is interrogated sequentially in \(250 \times 250 \mu \text{m}\) regions. The resulting scattered light pattern is recorded by a CMOS camera and analysed through a custom Matlab code to determine predominant collagen fibre directions.  
 
-The aim of the present study is to design and develop a fully automated SALS system capable of determining the changes in arterial fibre architecture in response to strain. 
+To validate the system, testing was conducted on test plates with known printed configurations. Once validated, SALS testing was carried out on flat porcine carotid artery wall sections fixed at different stretch ratios. Carotid artery samples were fixed and processed using a standard histological tissue sectioning protocol. Validation of the results was achieved through histological staining of the sections.  
 
-MATERIALS AND METHODS 
+## RESULTS  
 
-An in-house SALS system has been developed making use of an unpolarised 5mW HeNe laser (\(\lambda = 632.8 \, \text{nm}\)) and two focusing lenses in order to pass light through a tissue sample held in an automated sample positioner. The sample positioner incorporates two stepper motors controlled by LabVIEW to allow movement of the sample in the x and y plane with a resolution of \(5 \, \mu \text{m}\). The sample is interrogated sequentially in \(250 \times 250 \, \mu \text{m}\) regions. The resulting scattered light pattern is recorded by a CMOS camera and analysed through a custom Matlab code to determine predominant collagen fibre directions. 
+Figure 1a displays the collagen fibre directions in an unstretched carotid artery section, as predicted by SALS, overlaid on picrorisirus red stained histological images. Figure 1b shows the reorganisation of the constituent collagen fibres under circumferential stretch \((\lambda = 1.25)\) .  
 
-To validate the system, testing was conducted on test plates with known printed configurations. Once validated, SALS testing was carried out on flat porcine carotid artery wall sections fixed at different stretch ratios. Carotid artery samples were fixed and processed using a standard histological tissue sectioning protocol. Validation of the results was achieved through histological staining of the sections. 
+Collagen fibre patterns in the artery were also obtained through the thickness of the artery wall using SALS, for both strained and unstrained configurations.  
 
-RESULTS 
+![Figure sample_00006_fig05](figures/sample_00006_fig05.png)
 
-Figure 1a displays the collagen fibre directions in an unstretched carotid artery section, as predicted by SALS, overlaid on picrosirius red stained histological images. Figure 1b shows the reorganisation of the constituent collagen fibres under circumferential stretch (\(\lambda = 1.25\)). 
+<center>Figure 1 Fibre orientation as determined by SALS overlaid on histological carotid wall images. a) unstretched \((\lambda = 1)\) and b) stretched circumferentially \((\lambda = 1.25)\) </center>  
 
-Collagen fibre patterns in the artery were also obtained through the thickness of the artery wall using SALS, for both strained and unstrained configurations. 
+## DISCUSSION  
 
-![Figure sample_00006_fig01](figures/sample_00006_fig01.png)
- 
+Results shown in Figure 1 highlight the dependence of fibre orientation on the levels of stretch experienced by the artery wall. A clear realignment of collagen fibres in the direction of loading is visible from Figure 1a and 1b. Although these results are widely known and shown in literature, this is the first time they have been resolved through SALS.  
 
-<center>Figure 1 Fibre orientation as determined by SALS overlaid on histological carotid wall images. a) unstretched (\(\lambda = 1\)) and b) stretched circumferentially (\(\lambda = 1.25\)).</center> 
+Although SALS is limited to thin samples, time consuming staining protocols are not required for fibre characterisation. The speed, accuracy and ease of use of this system make it a powerful system for providing insights into the response of arterial tissue to load.  
 
-DISCUSSION 
+Future work aims to fully identify load induced tissue changes in healthy and diseased arterial tissue using SALS.  
 
-Results shown in Figure 1 highlight the dependence of fibre orientation on the levels of stretch experienced by the artery wall. A clear realignment of collagen fibres in the direction of loading is visible from Figure 1a and 1b. Although these results are widely known and shown in literature, this is the first time they have been resolved through SALS. 
+## REFERENCES  
 
-Although SALS is limited to thin samples, time consuming staining protocols are not required for fibre characterisation. The speed, accuracy and ease of use of this system make it a powerful system for providing insights into the response of arterial tissue to load. 
+[1] C. Creane et al., Biomech Model Mechanobiol., 10: 831- 843, 2011[2] Billiar, K., and Sacks, M., J. Biomech. 30: 753- 7 56, 1997  
 
-Future work aims to fully identify load induced tissue changes in healthy and diseased arterial tissue using SALS. 
-
-REFERENCES 
-
-[1] Creane et al., Biomech Model Mechanobiol., 10: 831-843, 2011
-[2] Billiar, K., and Sacks, M., J. Biomech. 30: 753-7 56, 1997 
-
-ACKNOWLEDGEMENTS 
+## ACKNOWLEDGEMENTS  
 
 This research was part funded by Science Foundation Ireland (SFI/13/ERC/B2775) and the Irish Research Council (GOIPG/2014/515).

sample_00006/raw_response.md

@@ -1,100 +1,82 @@
-1? (X) 
+1? (X)  
 
-<|ref|>text<|/ref|><|det|>[[153, 72, 344, 96]]<|/det|>
-Entry for the Engineers Ireland
-Biomedical Research Medal? (X) 
+<|ref|>text<|/ref|><|det|>[[154, 73, 347, 97]]<|/det|>
+Entry for the Engineers Ireland Biomedical Research Medal? (X)  
 
-<|ref|>text<|/ref|><|det|>[[487, 73, 770, 86]]<|/det|>
-Mature Researcher (Beyond PhD Year 1?) 
+<|ref|>image<|/ref|><|det|>[[374, 37, 411, 99]]<|/det|>  
 
-<|ref|>text<|/ref|><|det|>[[487, 77, 769, 90]]<|/det|>
-Post-Doctoral Researcher/Senior Researcher/PI 
+<|ref|>image<|/ref|><|det|>[[372, 37, 410, 99]]<|/det|>  
 
-<|ref|>text<|/ref|><|det|>[[151, 71, 362, 96]]<|/det|>
-Y 
+<|ref|>image<|/ref|><|det|>[[374, 37, 411, 99]]<|/det|>  
 
-<|ref|>text<|/ref|><|det|>[[151, 75, 363, 94]]<|/det|>
-Y 
+<|ref|>text<|/ref|><|det|>[[492, 45, 735, 58]]<|/det|>
+Mature Researcher (Beyond PhD Year 1?)  
 
-<|ref|>text<|/ref|><|det|>[[151, 97, 363, 110]]<|/det|>
-N 
+<|ref|>text<|/ref|><|det|>[[492, 75, 767, 88]]<|/det|>
+Post- Doctoral Researcher/Senior Researcher/PI  
 
-<|ref|>text<|/ref|><|det|>[[475, 110, 770, 123]]<|/det|>
-N 
+<|ref|>image<|/ref|><|det|>[[787, 41, 851, 95]]<|/det|>  
 
-<|ref|>sub_title<|/ref|><|det|>[[217, 113, 793, 146]]<|/det|>
-LOAD INDUCED CHANGES IN COLLAGEN FIBRE ARCHITECTURE IN ARTERIES
-CHARACTERISED BY SMALL ANGLE LIGHT SCATTERING 
+<|ref|>title<|/ref|><|det|>[[218, 113, 793, 147]]<|/det|>
+# LOAD INDUCED CHANGES IN COLLAGEN FIBRE ARCHITECTURE IN ARTERIES CHARACTERISED BY SMALL ANGLE LIGHT SCATTERING  
 
-<|ref|>text<|/ref|><|det|>[[292, 169, 767, 190]]<|/det|>
-Gaul, R.¹,², Lally, C.¹,² 
+<|ref|>text<|/ref|><|det|>[[242, 168, 767, 232]]<|/det|>
+Gaul, R.1,2, Lally, C.1,2 1Trinity Centre for Bioengineering, Trinity College Dublin, Dublin, Ireland. 2School of Engineering, Trinity College Dublin, Dublin, Ireland. email: rgau@tcd.ie  
 
-<|ref|>text<|/ref|><|det|>[[292, 187, 768, 203]]<|/det|>
-¹Trinity Centre for Bioengineering, Trinity College Dublin, Dublin, Ireland. 
+<|ref|>sub_title<|/ref|><|det|>[[144, 237, 270, 251]]<|/det|>
+## INTRODUCTION  
 
-<|ref|>text<|/ref|><|det|>[[292, 202, 741, 216]]<|/det|>
-²School of Engineering, Trinity College Dublin, Dublin, Ireland. 
+<|ref|>text<|/ref|><|det|>[[144, 258, 470, 362]]<|/det|>
+The structural strength of arteries is governed by reinforcing collagen fibres present in the vessel wall. Although healthy vessels are capable of fibre remodelling, unhealthy fibre remodelling patterns may be associated with disease [1]. A greater understanding of the remodelling of these fibres may provide greater insight into arteries at risk of disease and how arterial repair may be induced.  
 
-<|ref|>text<|/ref|><|det|>[[435, 216, 579, 231]]<|/det|>
-email: rgau@tcd.ie 
+<|ref|>text<|/ref|><|det|>[[144, 364, 470, 432]]<|/det|>
+Small angle light scattering (SALS) is a technique which has previously been used to determine the structure of thin, highly organised tissue structures, such as bovine pericardium and porcine aortic valve tissue [2].  
 
-<|ref|>sub_title<|/ref|><|det|>[[144, 238, 273, 252]]<|/det|>
-INTRODUCTION 
+<|ref|>text<|/ref|><|det|>[[144, 435, 470, 489]]<|/det|>
+The aim of the present study is to design and develop a fully automated SALS system capable of determining the changes in arterial fibre architecture in response to strain.  
 
-<|ref|>text<|/ref|><|det|>[[144, 259, 472, 362]]<|/det|>
-The structural strength of arteries is governed by reinforcing collagen fibres present in the vessel wall. Although healthy vessels are capable of fibre remodelling, unhealthy fibre remodelling patterns may be associated with disease [1]. A greater understanding of the remodelling of these fibres may provide greater insight into arteries at risk of disease and how arterial repair may be induced. 
+<|ref|>sub_title<|/ref|><|det|>[[146, 502, 367, 517]]<|/det|>
+## MATERIALS AND METHODS  
 
-<|ref|>text<|/ref|><|det|>[[144, 366, 472, 431]]<|/det|>
-Small angle light scattering (SALS) is a technique which has previously been used to determine the structure of thin, highly organised tissue structures, such as bovine pericardium and porcine aortic valve tissue [2]. 
+<|ref|>text<|/ref|><|det|>[[144, 524, 470, 680]]<|/det|>
+An in- house SALS system has been developed making use of an unpolarised 5mW HeNe laser \((\lambda = 632.8 \text{nm})\) and two focusing lenses in order to pass light through a tissue sample held in an automated sample positioner. The sample positioner incorporates two stepper motors controlled by LabVIEW to allow movement of the sample in the x and y plane with a resolution of \(5 \mu \text{m}\) . The sample is interrogated sequentially in \(250 \times 250 \mu \text{m}\) regions. The resulting scattered light pattern is recorded by a CMOS camera and analysed through a custom Matlab code to determine predominant collagen fibre directions.  
 
-<|ref|>text<|/ref|><|det|>[[144, 434, 472, 488]]<|/det|>
-The aim of the present study is to design and develop a fully automated SALS system capable of determining the changes in arterial fibre architecture in response to strain. 
+<|ref|>text<|/ref|><|det|>[[144, 683, 470, 788]]<|/det|>
+To validate the system, testing was conducted on test plates with known printed configurations. Once validated, SALS testing was carried out on flat porcine carotid artery wall sections fixed at different stretch ratios. Carotid artery samples were fixed and processed using a standard histological tissue sectioning protocol. Validation of the results was achieved through histological staining of the sections.  
 
-<|ref|>sub_title<|/ref|><|det|>[[144, 503, 369, 517]]<|/det|>
-MATERIALS AND METHODS 
+<|ref|>sub_title<|/ref|><|det|>[[144, 801, 222, 815]]<|/det|>
+## RESULTS  
 
-<|ref|>text<|/ref|><|det|>[[144, 525, 472, 680]]<|/det|>
-An in-house SALS system has been developed making use of an unpolarised 5mW HeNe laser (\(\lambda = 632.8 \, \text{nm}\)) and two focusing lenses in order to pass light through a tissue sample held in an automated sample positioner. The sample positioner incorporates two stepper motors controlled by LabVIEW to allow movement of the sample in the x and y plane with a resolution of \(5 \, \mu \text{m}\). The sample is interrogated sequentially in \(250 \times 250 \, \mu \text{m}\) regions. The resulting scattered light pattern is recorded by a CMOS camera and analysed through a custom Matlab code to determine predominant collagen fibre directions. 
+<|ref|>text<|/ref|><|det|>[[144, 822, 470, 901]]<|/det|>
+Figure 1a displays the collagen fibre directions in an unstretched carotid artery section, as predicted by SALS, overlaid on picrorisirus red stained histological images. Figure 1b shows the reorganisation of the constituent collagen fibres under circumferential stretch \((\lambda = 1.25)\) .  
 
-<|ref|>text<|/ref|><|det|>[[144, 684, 472, 788]]<|/det|>
-To validate the system, testing was conducted on test plates with known printed configurations. Once validated, SALS testing was carried out on flat porcine carotid artery wall sections fixed at different stretch ratios. Carotid artery samples were fixed and processed using a standard histological tissue sectioning protocol. Validation of the results was achieved through histological staining of the sections. 
+<|ref|>text<|/ref|><|det|>[[527, 237, 852, 277]]<|/det|>
+Collagen fibre patterns in the artery were also obtained through the thickness of the artery wall using SALS, for both strained and unstrained configurations.  
 
-<|ref|>sub_title<|/ref|><|det|>[[144, 802, 223, 816]]<|/det|>
-RESULTS 
+<|ref|>image<|/ref|><|det|>[[525, 289, 837, 412]]<|/det|>
+<|ref|>image_caption<|/ref|><|det|>[[527, 415, 851, 452]]<|/det|>
+<center>Figure 1 Fibre orientation as determined by SALS overlaid on histological carotid wall images. a) unstretched \((\lambda = 1)\) and b) stretched circumferentially \((\lambda = 1.25)\) </center>  
 
-<|ref|>text<|/ref|><|det|>[[144, 825, 472, 903]]<|/det|>
-Figure 1a displays the collagen fibre directions in an unstretched carotid artery section, as predicted by SALS, overlaid on picrosirius red stained histological images. Figure 1b shows the reorganisation of the constituent collagen fibres under circumferential stretch (\(\lambda = 1.25\)). 
+<|ref|>sub_title<|/ref|><|det|>[[527, 465, 630, 479]]<|/det|>
+## DISCUSSION  
 
-<|ref|>text<|/ref|><|det|>[[526, 238, 852, 277]]<|/det|>
-Collagen fibre patterns in the artery were also obtained through the thickness of the artery wall using SALS, for both strained and unstrained configurations. 
+<|ref|>text<|/ref|><|det|>[[527, 487, 851, 578]]<|/det|>
+Results shown in Figure 1 highlight the dependence of fibre orientation on the levels of stretch experienced by the artery wall. A clear realignment of collagen fibres in the direction of loading is visible from Figure 1a and 1b. Although these results are widely known and shown in literature, this is the first time they have been resolved through SALS.  
 
-<|ref|>image<|/ref|><|det|>[[526, 290, 837, 412]]<|/det|>
- 
+<|ref|>text<|/ref|><|det|>[[527, 581, 851, 647]]<|/det|>
+Although SALS is limited to thin samples, time consuming staining protocols are not required for fibre characterisation. The speed, accuracy and ease of use of this system make it a powerful system for providing insights into the response of arterial tissue to load.  
 
-<|ref|>image_caption<|/ref|><|det|>[[526, 413, 852, 450]]<|/det|>
-<center>Figure 1 Fibre orientation as determined by SALS overlaid on histological carotid wall images. a) unstretched (\(\lambda = 1\)) and b) stretched circumferentially (\(\lambda = 1.25\)).</center> 
+<|ref|>text<|/ref|><|det|>[[527, 650, 851, 690]]<|/det|>
+Future work aims to fully identify load induced tissue changes in healthy and diseased arterial tissue using SALS.  
 
-<|ref|>sub_title<|/ref|><|det|>[[526, 464, 630, 479]]<|/det|>
-DISCUSSION 
+<|ref|>sub_title<|/ref|><|det|>[[527, 705, 640, 719]]<|/det|>
+## REFERENCES  
 
-<|ref|>text<|/ref|><|det|>[[526, 487, 852, 579]]<|/det|>
-Results shown in Figure 1 highlight the dependence of fibre orientation on the levels of stretch experienced by the artery wall. A clear realignment of collagen fibres in the direction of loading is visible from Figure 1a and 1b. Although these results are widely known and shown in literature, this is the first time they have been resolved through SALS. 
+<|ref|>text<|/ref|><|det|>[[527, 727, 851, 780]]<|/det|>
+[1] C. Creane et al., Biomech Model Mechanobiol., 10: 831- 843, 2011[2] Billiar, K., and Sacks, M., J. Biomech. 30: 753- 7 56, 1997  
 
-<|ref|>text<|/ref|><|det|>[[526, 583, 852, 650]]<|/det|>
-Although SALS is limited to thin samples, time consuming staining protocols are not required for fibre characterisation. The speed, accuracy and ease of use of this system make it a powerful system for providing insights into the response of arterial tissue to load. 
+<|ref|>sub_title<|/ref|><|det|>[[527, 793, 717, 807]]<|/det|>
+## ACKNOWLEDGEMENTS  
 
-<|ref|>text<|/ref|><|det|>[[526, 653, 852, 693]]<|/det|>
-Future work aims to fully identify load induced tissue changes in healthy and diseased arterial tissue using SALS. 
-
-<|ref|>sub_title<|/ref|><|det|>[[526, 707, 641, 722]]<|/det|>
-REFERENCES 
-
-<|ref|>text<|/ref|><|det|>[[526, 730, 852, 781]]<|/det|>
-[1] Creane et al., Biomech Model Mechanobiol., 10: 831-843, 2011
-[2] Billiar, K., and Sacks, M., J. Biomech. 30: 753-7 56, 1997 
-
-<|ref|>sub_title<|/ref|><|det|>[[526, 796, 716, 810]]<|/det|>
-ACKNOWLEDGEMENTS 
-
-<|ref|>text<|/ref|><|det|>[[526, 817, 852, 856]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[527, 814, 851, 853]]<|/det|>
 This research was part funded by Science Foundation Ireland (SFI/13/ERC/B2775) and the Irish Research Council (GOIPG/2014/515).

sample_00007/document.md

@@ -1 +1 @@
-2011, XLVI, 394 p., HardcoverISBN: 978-90-481-8664-8
+2011, XLV, 394 p., Hardcover ISBN: 978-90-481-8664-8

sample_00007/raw_response.md

@@ -1 +1 @@
-2011, XLVI, 394 p., HardcoverISBN: 978-90-481-8664-8
+2011, XLV, 394 p., Hardcover ISBN: 978-90-481-8664-8

sample_00008/document.md

@@ -1,17 +1,17 @@
-The parametric equations for a projectile with constant gravity g:  
+The parametric equations for a projectile with constant gravity g: 
 
-\[x = \nu_{0}t\cos \theta +x_{0}\]  
+\[x = v_0 t \cos \theta + x_0\]
 
-\[y = -\frac{1}{2} gt^{2} + \nu_{0}t\sin \theta +y_{0}\]  
+\[y = -\frac{1}{2} gt^2 + v_0 t \sin \theta + y_0\]
 
-ex. A shell is fired from ground level with an initial speed of 768 ft/sec. at an angle of 30°. Find:  
+ex. A shell is fired from ground level with an initial speed of 768 ft/sec. at an angle of 30°. Find: 
 
-1. \(\vec{r} (t)\)  
+1. \(\vec{r}(t)\) 
 
-2. the maximum altitude attained  
+2. the maximum altitude attained 
 
-3. the range of the shell  
+3. the range of the shell 
 
-4. the speed on impact  
+4. the speed on impact 
 
 5. the horizontal distance when \(y = 2240\) ft.

sample_00008/raw_response.md

@@ -1,26 +1,26 @@
-<|ref|>text<|/ref|><|det|>[[89, 80, 860, 108]]<|/det|>
-The parametric equations for a projectile with constant gravity g:  
+<|ref|>text<|/ref|><|det|>[[91, 80, 860, 107]]<|/det|>
+The parametric equations for a projectile with constant gravity g: 
 
-<|ref|>equation<|/ref|><|det|>[[151, 110, 422, 145]]<|/det|>
-\[x = \nu_{0}t\cos \theta +x_{0}\]  
+<|ref|>equation<|/ref|><|det|>[[152, 107, 426, 140]]<|/det|>
+\[x = v_0 t \cos \theta + x_0\]
 
-<|ref|>equation<|/ref|><|det|>[[151, 156, 566, 227]]<|/det|>
-\[y = -\frac{1}{2} gt^{2} + \nu_{0}t\sin \theta +y_{0}\]  
+<|ref|>equation<|/ref|><|det|>[[152, 153, 565, 227]]<|/det|>
+\[y = -\frac{1}{2} gt^2 + v_0 t \sin \theta + y_0\]
 
-<|ref|>text<|/ref|><|det|>[[88, 254, 866, 308]]<|/det|>
-ex. A shell is fired from ground level with an initial speed of 768 ft/sec. at an angle of 30°. Find:  
+<|ref|>text<|/ref|><|det|>[[89, 255, 866, 308]]<|/det|>
+ex. A shell is fired from ground level with an initial speed of 768 ft/sec. at an angle of 30°. Find: 
 
-<|ref|>text<|/ref|><|det|>[[90, 310, 178, 353]]<|/det|>
-1. \(\vec{r} (t)\)  
+<|ref|>text<|/ref|><|det|>[[92, 309, 182, 351]]<|/det|>
+1. \(\vec{r}(t)\) 
 
-<|ref|>text<|/ref|><|det|>[[90, 357, 484, 382]]<|/det|>
-2. the maximum altitude attained  
+<|ref|>text<|/ref|><|det|>[[92, 357, 484, 380]]<|/det|>
+2. the maximum altitude attained 
 
-<|ref|>text<|/ref|><|det|>[[91, 383, 372, 408]]<|/det|>
-3. the range of the shell  
+<|ref|>text<|/ref|><|det|>[[92, 383, 372, 407]]<|/det|>
+3. the range of the shell 
 
-<|ref|>text<|/ref|><|det|>[[91, 410, 361, 434]]<|/det|>
-4. the speed on impact  
+<|ref|>text<|/ref|><|det|>[[92, 409, 360, 433]]<|/det|>
+4. the speed on impact 
 
-<|ref|>text<|/ref|><|det|>[[91, 436, 606, 461]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[92, 436, 607, 460]]<|/det|>
 5. the horizontal distance when \(y = 2240\) ft.

sample_00009/document.md

@@ -1,18 +1,18 @@
-purpose of attenuation correction. The scanning parameters may vary according to the type of CT scanner. Usually the tube voltage is set at \(140 \text{kV}\) , which permits the conversion of the Hounsfield units into attenuation coefficients at 511 keV. The CT scan can be performed after the injection of FDG and has the advantage to significantly reduce the total scan time (usual duration is \(<10 \text{s}\) ). However, the dose of the CT scan to the patient can be reduced by lowering the tube current (see radiation dosimetry above) if anatomical information is not needed. When performing PET-CT of the brain it is recommended to check for movements between the CT and the PET sessions, which might produce artefacts in the attenuation correction. 
+purpose of attenuation correction. The scanning parameters may vary according to the type of CT scanner. Usually the tube voltage is set at \(140\mathrm{kV}\) , which permits the conversion of the Hounsfield units into attenuation coefficients at 511 keV. The CT scan can be performed after the injection of FDG and has the advantage to significantly reduce the total scan time (usual duration is \(<10\mathrm{s}\) ). However, the dose of the CT scan to the patient can be reduced by lowering the tube current (see radiation dosimetry above) if anatomical information is not needed. When performing PET-CT of the brain it is recommended to check for movements between the CT and the PET sessions, which might produce artefacts in the attenuation correction. 
 
-- Emission scan. As semiquantitative estimates of tumor-to-background uptake ratios are typically used, it is recommended to use a standardized acquisition protocol with a fixed time for start of acquisition to make the data of different patients or repeated scans comparable. If data are acquired in 3-D mode, appropriate scatter correction is mandatory. The duration of emission image acquisition should be related to the minimum required number of counts. For FDG, typically data are acquired over \(15-30 \text{min}\) aiming to collect \(50-200 \text{million counts}\). Even though shorter acquisition times can still be used for diagnostic pattern evaluation (Chen et al. 2005), a minimum of 15 min in 3D mode is advocated. For MET and FET typically data are acquired for 20 min (20-40 min p.i.), often supplemented by dynamic data starting directly with tracer injection. 
+- Emission scan. As semiquantitative estimates of tumor-to-background uptake ratios are typically used, it is recommended to use a standardized acquisition protocol with a fixed time for start of acquisition to make the data of different patients or repeated scans comparable. If data are acquired in 3-D mode, appropriate scatter correction is mandatory. The duration of emission image acquisition should be related to the minimum required number of counts. For FDG, typically data are acquired over \(15–30\mathrm{min}\) aiming to collect \(50–200\mathrm{million}\) counts. Even though shorter acquisition times can still be used for diagnostic pattern evaluation (Chen et al. 2005), a minimum of \(15\mathrm{min}\) in 3D mode is advocated. For MET and FET typically data are acquired for \(20\mathrm{min}\) (20–40 min p.i.), often supplemented by dynamic data starting directly with tracer injection. 
 
 ## IMT Single Photon Emission Tomography 
 
 - Multiple detectors (triple or dual head) or other dedicated SPECT cameras for brain imaging should be used for acquisition. Single detector units cannot generally be recommended. They may only be used if scan time is prolonged appropriately, a dose in the upper suggested range is applied, and meticulous care is taken to produce high-quality images. 
 
-- LEHR or LEUHR parallel-hole collimators are the mostly available collimator sets for brain imaging. All purpose collimators are not suitable. The use of medium energy collimators could be advantageous; however, usually they are hampered by a low sensitivity. They may only be used if acceptable count rates are obtained. If available, collimator sets specifically adapted to the characteristics of \(^{123}\text{I}\) may be used. Fanbeam collimators may be generally preferred over parallel-hole collimators due to the advantageous trade-off between resolution and count rate capability. The acquisition parameters are summarized in Table 2.2. 
+- LEHR or LEUHR parallel-hole collimators are the mostly available collimator sets for brain imaging. All purpose collimators are not suitable. The use of medium energy collimators could be advantageous; however, usually they are hampered by a low sensitivity. They may only be used if acceptable count rates are obtained. If available, collimator sets specifically adapted to the characteristics of \(^{123}\mathrm{I}\) may be used. Fan-beam collimators may be generally preferred over parallel-hole collimators due to the advantageous trade-off between resolution and count rate capability. The acquisition parameters are summarized in Table 2.2. 
 
 TABLE 2.2. Acquisition parameters for IMT-SPECT 
 
 - Rotational radius: smallest possible with appropriate patient safeguard
 - Matrix: \(128 \times 128\)
-- Angular sampling: \(\leq 3^\circ\) (360° rotation)
-- Zoom: acquisition pixel size should be \(1/3-1/2\) of the expected resolution; therefore it may be necessary to use a hardware zoom to achieve an appropriate pixel size
+- Angular sampling: \(\leq 3^\circ (360^\circ \text{ rotation})\)
+- Zoom: acquisition pixel size should be \(1/3–1/2\) of the expected resolution; therefore it may be necessary to use a hardware zoom to achieve an appropriate pixel size
 - Acquisition mode: Step and shoot mode is predominantly used. Continuous mode acquisition may provide shorter total scan time, reduce mechanical wear to the system and improve patient comfort
-- Total scan time: depending on the imaging device, typical scan time for a triple head camera is about 30-50 min (e.g., 120 projections; 40 projections per head; 60 s/projection)
+- Total scan time: depending on the imaging device, typical scan time for a triple head camera is about \(30–50\mathrm{min}\) (e.g., 120 projections; 40 projections per head; 60 s/projection)

sample_00009/raw_response.md

@@ -1,25 +1,25 @@
-<|ref|>text<|/ref|><|det|>[[137, 87, 492, 440]]<|/det|>
-purpose of attenuation correction. The scanning parameters may vary according to the type of CT scanner. Usually the tube voltage is set at \(140 \text{kV}\) , which permits the conversion of the Hounsfield units into attenuation coefficients at 511 keV. The CT scan can be performed after the injection of FDG and has the advantage to significantly reduce the total scan time (usual duration is \(<10 \text{s}\) ). However, the dose of the CT scan to the patient can be reduced by lowering the tube current (see radiation dosimetry above) if anatomical information is not needed. When performing PET-CT of the brain it is recommended to check for movements between the CT and the PET sessions, which might produce artefacts in the attenuation correction. 
+<|ref|>text<|/ref|><|det|>[[137, 87, 492, 437]]<|/det|>
+purpose of attenuation correction. The scanning parameters may vary according to the type of CT scanner. Usually the tube voltage is set at \(140\mathrm{kV}\) , which permits the conversion of the Hounsfield units into attenuation coefficients at 511 keV. The CT scan can be performed after the injection of FDG and has the advantage to significantly reduce the total scan time (usual duration is \(<10\mathrm{s}\) ). However, the dose of the CT scan to the patient can be reduced by lowering the tube current (see radiation dosimetry above) if anatomical information is not needed. When performing PET-CT of the brain it is recommended to check for movements between the CT and the PET sessions, which might produce artefacts in the attenuation correction. 
 
-<|ref|>text<|/ref|><|det|>[[115, 444, 492, 897]]<|/det|>
-- Emission scan. As semiquantitative estimates of tumor-to-background uptake ratios are typically used, it is recommended to use a standardized acquisition protocol with a fixed time for start of acquisition to make the data of different patients or repeated scans comparable. If data are acquired in 3-D mode, appropriate scatter correction is mandatory. The duration of emission image acquisition should be related to the minimum required number of counts. For FDG, typically data are acquired over \(15-30 \text{min}\) aiming to collect \(50-200 \text{million counts}\). Even though shorter acquisition times can still be used for diagnostic pattern evaluation (Chen et al. 2005), a minimum of 15 min in 3D mode is advocated. For MET and FET typically data are acquired for 20 min (20-40 min p.i.), often supplemented by dynamic data starting directly with tracer injection. 
+<|ref|>text<|/ref|><|det|>[[113, 441, 492, 896]]<|/det|>
+- Emission scan. As semiquantitative estimates of tumor-to-background uptake ratios are typically used, it is recommended to use a standardized acquisition protocol with a fixed time for start of acquisition to make the data of different patients or repeated scans comparable. If data are acquired in 3-D mode, appropriate scatter correction is mandatory. The duration of emission image acquisition should be related to the minimum required number of counts. For FDG, typically data are acquired over \(15–30\mathrm{min}\) aiming to collect \(50–200\mathrm{million}\) counts. Even though shorter acquisition times can still be used for diagnostic pattern evaluation (Chen et al. 2005), a minimum of \(15\mathrm{min}\) in 3D mode is advocated. For MET and FET typically data are acquired for \(20\mathrm{min}\) (20–40 min p.i.), often supplemented by dynamic data starting directly with tracer injection. 
 
-<|ref|>sub_title<|/ref|><|det|>[[511, 83, 826, 99]]<|/det|>
+<|ref|>sub_title<|/ref|><|det|>[[511, 82, 826, 97]]<|/det|>
 ## IMT Single Photon Emission Tomography 
 
-<|ref|>text<|/ref|><|det|>[[511, 108, 886, 299]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[511, 108, 887, 297]]<|/det|>
 - Multiple detectors (triple or dual head) or other dedicated SPECT cameras for brain imaging should be used for acquisition. Single detector units cannot generally be recommended. They may only be used if scan time is prolonged appropriately, a dose in the upper suggested range is applied, and meticulous care is taken to produce high-quality images. 
 
-<|ref|>text<|/ref|><|det|>[[511, 302, 886, 618]]<|/det|>
-- LEHR or LEUHR parallel-hole collimators are the mostly available collimator sets for brain imaging. All purpose collimators are not suitable. The use of medium energy collimators could be advantageous; however, usually they are hampered by a low sensitivity. They may only be used if acceptable count rates are obtained. If available, collimator sets specifically adapted to the characteristics of \(^{123}\text{I}\) may be used. Fanbeam collimators may be generally preferred over parallel-hole collimators due to the advantageous trade-off between resolution and count rate capability. The acquisition parameters are summarized in Table 2.2. 
+<|ref|>text<|/ref|><|det|>[[511, 300, 888, 619]]<|/det|>
+- LEHR or LEUHR parallel-hole collimators are the mostly available collimator sets for brain imaging. All purpose collimators are not suitable. The use of medium energy collimators could be advantageous; however, usually they are hampered by a low sensitivity. They may only be used if acceptable count rates are obtained. If available, collimator sets specifically adapted to the characteristics of \(^{123}\mathrm{I}\) may be used. Fan-beam collimators may be generally preferred over parallel-hole collimators due to the advantageous trade-off between resolution and count rate capability. The acquisition parameters are summarized in Table 2.2. 
 
-<|ref|>table_caption<|/ref|><|det|>[[511, 686, 855, 701]]<|/det|>
+<|ref|>table_caption<|/ref|><|det|>[[511, 685, 857, 699]]<|/det|>
 TABLE 2.2. Acquisition parameters for IMT-SPECT 
 
-<|ref|>text<|/ref|><|det|>[[511, 707, 880, 893]]<|/det|>
+<|ref|>text<|/ref|><|det|>[[511, 707, 880, 890]]<|/det|>
 - Rotational radius: smallest possible with appropriate patient safeguard
 - Matrix: \(128 \times 128\)
-- Angular sampling: \(\leq 3^\circ\) (360° rotation)
-- Zoom: acquisition pixel size should be \(1/3-1/2\) of the expected resolution; therefore it may be necessary to use a hardware zoom to achieve an appropriate pixel size
+- Angular sampling: \(\leq 3^\circ (360^\circ \text{ rotation})\)
+- Zoom: acquisition pixel size should be \(1/3–1/2\) of the expected resolution; therefore it may be necessary to use a hardware zoom to achieve an appropriate pixel size
 - Acquisition mode: Step and shoot mode is predominantly used. Continuous mode acquisition may provide shorter total scan time, reduce mechanical wear to the system and improve patient comfort
-- Total scan time: depending on the imaging device, typical scan time for a triple head camera is about 30-50 min (e.g., 120 projections; 40 projections per head; 60 s/projection)
+- Total scan time: depending on the imaging device, typical scan time for a triple head camera is about \(30–50\mathrm{min}\) (e.g., 120 projections; 40 projections per head; 60 s/projection)